On August 15, the AI Innovation-Driven High-Quality Development Conference for Traditional Chinese Medicine was held in Guangzhou. At the conference, Lin Xiaoyan, Vice President of GUSHENGTANG (02273) TCM Group, delivered a presentation titled "Leading TCM Internationalization - Making TCM Mainstream Global Healthcare," systematically outlining the company's strategic layout using the "three pillars" of management empowerment + AI technology + products to drive TCM internationalization, committed to building the world's leading TCM healthcare brand for the global Chinese community.
**I. Management Going Global: Mature Model Empowerment, "Self-Built + M&A" Strategy Building Overseas Territory**
In March 2024, GUSHENGTANG acquired Singapore's Bao Zhong Tang, officially launching its new international journey. By replicating its mature domestic operating model, Singapore Bao Zhong Tang achieved remarkable performance growth within just one year: July 2025 revenue increased 119% year-over-year, with expert first-visit return rates and on-site appointment rates ranking among the top within the group.
"The success in the Singapore market validates our internationalization model," said Lin Xiaoyan, Vice President of GUSHENGTANG. "We will continue to increase investment and expect to expand to 30 clinics in Singapore by the end of 2026."
After over 10 years of intensive development, GUSHENGTANG has formed a mature market expansion methodology. In overseas markets, the company will adopt a multi-modal strategy of "self-built + M&A + partnerships" to expand business scale: First, building flagship stores to rapidly enhance brand recognition among consumers. Second, strategic cooperation and integration, with plans to partner with local TCM chain institutions in Singapore to achieve overall performance growth. Third, M&A and cross-shareholding, collaborating with local Western medicine clinic chains for mutual investment on one hand, and acquiring quality Western medicine clinics and general hospitals on the other, achieving synergistic development of "TCM + Western medicine."
Simultaneously, GUSHENGTANG is exporting its mature domestic digital operation system overseas. In patient operations, GUSHENGTANG has developed an AI doctor health assistant that provides intelligent triage, health Q&A and other personalized services across multiple service scenarios including pre-consultation, during consultation, and post-consultation, building a complete service chain from first visit to follow-up, medication, recuperation, and return visits, continuously improving patient satisfaction and enhancing patient loyalty.
In system platform support, GUSHENGTANG now possesses six fully self-developed information platforms, including clinic digital management systems, HIS prescription systems, CRM management systems, social platform customer acquisition matrices, operations back-office support systems, and insurance settlement systems, providing comprehensive IT support for overseas TCM clinics.
**II. AI Technology Going Global: Launch of 10 National Medical AI Avatars, Global Supply of Top Medical Resources**
AI technology brings new opportunities for TCM internationalization development. At this conference, GUSHENGTANG launched 10 national medical AI avatars, solving the problem of scarce quality TCM talent overseas and accelerating TCM's global expansion.
GUSHENGTANG's national medical AI avatars are built based on the clinical experience of 10 renowned physicians: National TCM Master Shi Qi, National Famous TCM Doctor Cai Gan, Guangdong Famous TCM Doctor Ding Guo'an, renowned oncology expert He Yonghe, Guangdong Famous TCM Doctor Huang Suiping, National Famous Senior TCM Expert Li Haisong, Guangdong Famous TCM Doctor Li Hao, renowned classical formula expert Ouyang Weiquan, Guangdong Famous TCM Doctor Ruan Yan, and Shanghai Famous TCM Doctor Xu Zhenye. These AI avatars can assist experts in providing "online follow-up" services, opening new service pathways for experts with high offline consultation demand.
Currently, AI avatars have achieved over 86% consistency in expert simulation, with diagnostic accuracy and medication rationality highly praised by the experts themselves. By digitally preserving the diagnostic experience and syndrome differentiation thinking of renowned senior TCM doctors, GUSHENGTANG's national medical AI avatars demonstrate multi-faceted application value: First, assisting experts in handling routine diagnostic tasks, allowing experts to focus on core decision-making processes, thereby improving the diagnostic efficiency of top experts and alleviating the scarcity of quality TCM resources and the "hard-to-get appointments" problem with famous doctors. Second, the system intelligently assists young doctors in conducting diagnostic work, helping them master famous doctors' diagnostic thinking and effectively shortening the growth cycle from apprenticeship to independent practice. Third, through internet hospital platforms, overseas TCM practitioners using national medical AI avatars can learn clinical thinking from China's top experts, improving Singapore's overall expert level while better serving patients.
Additionally, relying on TCM inheritance workshops in Singapore, GUSHENGTANG is sending excellent domestic TCM practitioners overseas, helping breakthrough overseas medical resources and service capabilities. It's evident that AI technology not only improves quality and efficiency for GUSHENGTANG's domestic business but also plays a key role in its global expansion journey. With national medical AI avatars, GUSHENGTANG breaks down barriers of uneven TCM talent distribution between domestic and overseas markets, achieving digital inheritance and global supply of famous doctor experience, undoubtedly opening greater development space for GUSHENGTANG's overseas business.
**III. Product Going Global: First TCM Patent Medicine Receives Singapore Certification, Famous Doctor Experience Crosses Borders to Benefit People**
In the inheritance and development of TCM, patent medicines play an irreplaceable important role. GUSHENGTANG has had forward-looking layout in hospital preparation research and innovative patent medicine incubation. At the end of 2023, GUSHENGTANG partnered with West China Hospital's China Evidence-Based Medicine Center and Baidu to jointly launch the "TCM Big Model Clinical Evaluation Integration Platform" project, aimed at solving clinical assessment challenges for TCM in real-world data.
Through artificial intelligence big models, GUSHENGTANG will build an integrated platform covering TCM-characteristic big data governance, clinical evaluation, clinical recommendations, and TCM formula research, taking TCM clinical research integration and innovative drug development into a new journey.
Building research platforms requires high-quality data assets. Over 10+ years of development, GUSHENGTANG has accumulated rich and high-quality TCM data resources, including over 17 million consultation records, over 8 million medical record data, over 20 million prescriptions, plus high-quality medical cases from 8 National TCM Masters and tens of thousands of high-level TCM practitioners.
With powerful support from big data and artificial intelligence technology, GUSHENGTANG continues to drive the development of hospital preparations toward innovative patent medicines. Currently, GUSHENGTANG's 16 hospital preparations have completed registration and entered clinical use. Among them, the Hair Care and Growth Granules, developed with the life's work of National TCM Master Professor Xuan Guowei, has passed Singapore Health Sciences Authority (HSA) certification, becoming GUSHENGTANG's first self-developed patent medicine overseas.
In the future, GUSHENGTANG will intensify hospital preparation research efforts, developing same-name same-formula medicines and classical famous formula medicines, building a powerful Chinese innovative patent medicine service platform system, allowing famous doctor experience to be permanently inherited through medicines.
Using Singapore as a bridgehead, GUSHENGTANG is deeply integrating traditional TCM with modern technology through the "management + AI + products" three pillars. From Singapore market's 119% performance growth, to the first patent medicine's overseas certification, to AI technology's global application, GUSHENGTANG is writing a new chapter in TCM internationalization, steadily advancing toward the goal of becoming the "world's leading TCM brand for the global Chinese community."